Astrana Health, Inc. ASTH R2KR3KPHARMA

Q: What is the current share price of Astrana Health, Inc. (ASTH)?

As of 2026-09-07 16:24 PDT, Astrana Health, Inc. (ASTH) trades at $38.47 on NasdaqCM. Its 52-week range is $18.16 to $49.81.

Q: What is the market capitalisation of ASTH?

Astrana Health, Inc. (ASTH) has a market capitalisation of $1.91B on NasdaqCM.

Q: What is the P/E ratio of ASTH?

ASTH trades at a trailing price-to-earnings (P/E) ratio of 63.07. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.19.

Q: What is the return on equity (ROE) of ASTH?

ASTH has a return on equity (ROE) of 5.66%. Its return on capital employed (ROCE) is 4.90%.

Q: Is ASTH a good stock to buy?

This page provides a data-driven analysis of Astrana Health, Inc. (ASTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Care Facilities · United States

https://www.astranahealth.com

Company Profile ↓

$38.47

+29.83% 1Y

Mkt Cap$1.91B

P/E63.07

P/B2.19

52W High$49.81

52W Low$18.16

Book Value$16.35

EPS (TTM)$0.61

Company Overview

Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 56.4% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $3.18B (+56.4% YoY); net profit $22.49M.
Trailing 12 Months Year-on-year growth — revenue +55.6%, earnings +110.1%.
5-Year Trend Long-term compounding — revenue CAGR 56.4%, profit CAGR 9.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	56.36%
1 Year:	55.60%

Compounded Profit Growth

5 Years:	9.76%
1 Year:	110.10%

Stock Price Performance

1 Year:	+29.83%
6 Months:	+54.44%
3 Months:	+1.26%
1 Month:	+12.72%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 64% of range

$18.16 $49.81

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)49.25 · Neutral

Price Performance

1M+12.72%

3M+1.26%

6M+54.44%

1Y+29.83%

Valuation vs Sector

P/E of 63.07 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 56.4% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 63.1.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

63.07

Industry PE

25.17

Forward P/E

11.25

PEG Ratio

Book Value

$16.35

Price to Book

2.19

P/S

0.50

EV/EBITDA

11.91

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

56.36%

Profit 5Y

9.76%

Revenue (YoY)

55.60%

Earnings (YoY)

110.10%

Profitability & Returns

ROCE

4.90%

ROE

5.66%

ROA

3.56%

Profit Margin

0.86%

Op Margin

3.02%

Gross Margin

10.66%

EPS (Latest Qtr)

$0.29

EPS (TTM)

$0.61

Balance Sheet & Liquidity

Debt/Equity

1.84

Quick Ratio

1.31

Current Ratio

1.35

Debt

$1.07B

Total Assets

$2.36B

Current Assets

$1.00B

Working Capital

$248.04M

Ownership

Promoter Holding

22.85%

Chg in Prom Hold

-0.02%

FII / Inst Holding

66.17%

Chg in FII Hold

0.03%

Financial Snapshot

Enterprise Value

$1.91B

Total Revenue (TTM)

$3.53B

EBITDA

$159.62M

Free Cash Flow

$287.76M

Operating Cash Flow

$166.03M

Shares Outstanding

49.58M

Gross Margin

10.66%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ASTH Astrana Health, Inc. R2KR3KPHARMA	38.47	63.07	$1.91B	0.00%	4.90%	5.66%	56.36%	9.76%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Dec 2014	Jun 2015	Sep 2015	Dec 2015	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	122.67M	166.73M	95.76M	130.05M	156.06M	178.75M	165.10M	165.17M	180.12M	176.78M	176.06M	175.64M	227.12M	263.26M	269.70M	317.00M	337.24M	348.21M	348.17M	404.36M	486.26M	478.71M	620.39M	654.81M	956.05M	950.53M	965.10M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	549.06M	576.84M	858.86M	855.48M	859.36M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71.33M	77.97M	97.19M	95.04M	105.74M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50.75M	57.63M	77.98M	76.65M	77.22M
Operating Income	-1.19M	1.86M	-1.53M	-1.66M	-412.91K	-1.46M	-1.76M	-2.17M	-1.68M	15.68M	4.06M	21.25M	22.70M	7.15M	56.58M	-3.31M	14.73M	10.07M	10.93M	4.37M	12.91M	37.36M	25.88M	21.78M	20.99M	53.16M	26.21M	15.38M	50.09M	22.37M	27.03M	39.08M	30.14M	30.07M	28.43M	20.58M	20.34M	19.21M	18.39M	28.53M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.76M	31.11M	38.98M	41.43M	51.29M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.31M	7.38M	17.72M	17.52M	16.10M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.60M	16.82M	5.67M	7.51M	19.71M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.38M	6.61M	4.59M	944.00K	6.58M
Net Income	-1.68M	1.38M	-1.69M	-2.48M	-531.37K	-1.69M	-1.32M	-1.36M	-1.73M	4.35M	1.99M	5.62M	2.16M	2.66M	9.11M	140.00K	3.54M	3.70M	6.73M	4.05M	7.04M	16.71M	10.06M	13.15M	12.66M	34.28M	14.26M	11.95M	23.18M	13.13M	13.17M	22.06M	14.84M	19.17M	16.09M	6.69M	9.42M	373.00K	6.00M	14.44M
Diluted EPS	-	0.26	-0.35	-	-0.11	-0.31	-	-	-	0.15	0.07	0.20	0.06	0.07	0.24	0.00	0.09	0.10	0.18	0.11	0.19	0.45	0.26	0.30	0.28	0.74	0.31	0.26	0.50	0.28	0.28	0.47	0.31	0.40	0.33	0.14	0.19	0.01	0.12	0.29

Profit & Loss (Annual)

Figures in USD.

Metric	Jan 2011	Jan 2012	Jan 2013	Jan 2014	Mar 2015	Mar 2016	Dec 2016	Mar 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	3.90M	5.11M	7.78M	10.48M	32.99M	44.05M	305.93M	57.43M	356.36M	519.91M	560.62M	687.18M	-	1.14B	1.39B	2.03B	3.18B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	944.68M	1.17B	1.76B	2.84B
Gross Profit	581.86K	978.41K	1.46M	1.41M	-	-	-	-	-	-	-	-	-	199.48M	214.96M	271.39M	341.53M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	95.21M	130.34M	182.04M	263.00M
Operating Income	4.01K	-413.33K	-2.08M	-3.91M	-694.33K	-7.27M	11.69M	-10.54M	35.15M	88.43M	32.42M	80.50M	-	104.27M	84.61M	89.35M	78.53M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	112.08M	123.69M	141.84M	135.28M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	7.92M	16.10M	33.10M	49.93M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	86.62M	89.84M	80.82M	39.61M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	40.88M	31.99M	30.89M	15.53M
Net Income	-156.33K	-720.35K	-8.90M	-5.02M	-1.80M	-9.34M	11.45M	-8.97M	25.80M	10.84M	14.12M	37.87M	-	45.17M	60.72M	43.15M	22.49M
Diluted EPS	-	-	-	-	-	-	0.41	-	0.90	0.29	0.39	1.01	-	1.08	1.29	0.90	0.46

Balance Sheet (Annual)

Figures in USD.

Metric	Jan 2010	Jan 2011	Jan 2012	Jan 2013	Jan 2014	Mar 2014	Mar 2015	Dec 2015	Mar 2016	Dec 2016	Mar 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	1.26M	1.36M	3.22M	3.96M	9.48M	15.00M	-	19.57M	350.00M	20.64M	490.64M	513.00M	728.71M	817.49M	-	966.21M	933.36M	1.35B	2.22B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	428.12M	461.51M	638.50M	863.31M
Cash & Equivalents	665.74K	397.10K	164.36K	1.18M	1.45M	6.83M	5.01M	59.01M	9.27M	54.82M	8.66M	99.75M	106.89M	103.19M	193.47M	-	288.03M	293.81M	288.45M	429.47M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49.63M	76.78M	275.99M	374.46M
Total Liabilities	-	1.34M	1.79M	3.61M	5.65M	11.11M	15.99M	-	11.02M	99.56M	20.37M	154.32M	106.34M	367.65M	372.34M	-	407.67M	522.59M	840.73M	1.66B
Current Liabilities	-	92.75K	1.52M	1.70M	4.55M	2.32M	5.97M	-	7.43M	50.63M	14.54M	109.60M	72.02M	105.42M	114.99M	-	148.61M	218.67M	365.61M	615.27M
Long Term Debt	-	-	-	-	-	-	10.72M	-	-	-	-	-	0	232.17M	230.21M	-	203.39M	258.94M	425.30M	990.90M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	229.36M	321.01M	470.68M	1.08B
Total Equity	-46.39K	-311.31K	-659.32K	-354.88K	-2.62M	-2.41M	-2.82M	84.50M	-1.27M	87.21M	-353.88K	159.95M	180.55M	191.55M	330.82M	-	542.56M	614.22M	712.72M	779.29M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56.87M	57.43M	58.53M	59.46M

Cash Flows (Annual)

Figures in USD.

Metric	Jan 2011	Jan 2012	Jan 2013	Jan 2014	Mar 2015	Mar 2016	Dec 2016	Mar 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-245.03K	-385.45K	57.96K	-1.48M	-	-	21.91M	-	51.83M	25.50M	13.67M	46.16M	-	82.13M	68.23M	52.20M	114.60M
Investing Cash Flow	-21.16K	157.00K	-31.68K	-272.93K	-	-	-8.96M	-	26.72M	-25.18M	-180.63M	95.49M	-	-7.11M	-65.52M	-192.40M	-539.00M
Financing Cash Flow	-2.44K	-4.29K	986.10K	2.03M	-	-	-17.15M	-	-14.98M	-11.18M	163.33M	-51.70M	-	-20.09M	3.42M	135.15M	569.35M
Capital Expenditure	-21.16K	-7.21K	-45.80K	-22.93K	-44.51K	-262.11K	-3.31M	-297.56K	-2.08M	-1.17M	-1.04M	-1.16M	-	-22.94M	-28.53M	-8.03M	-10.11M
Free Cash Flow	-266.20K	-392.66K	12.16K	-1.50M	-	-	18.61M	-	49.75M	24.33M	12.63M	45.00M	-	59.19M	39.70M	44.17M	104.49M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	54.93M	6.12M	-5.05M	144.94M
Share Buybacks	-	-	-	0	500	-	517.50K	-	3.18M	5.05M	7.57M	537.00K	5.74M	9.25M	10.19M	900.00K	25.60M
Dividends Paid	-	-	-	-	-	-	26.66M	-	10.45M	17.76M	61.72M	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Jan 2011	Jan 2012	Jan 2013	Jan 2014	Mar 2015	Mar 2016	Dec 2016	Mar 2017	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	14.9%	19.1%	18.8%	13.4%	-	-	-	-	-	-	-	-	-	17.4%	15.5%	13.3%	10.7%
Operating Margin %	0.1%	-8.1%	-26.7%	-37.3%	-2.1%	-16.5%	3.8%	-18.3%	9.9%	17.0%	5.8%	11.7%	-	9.1%	6.1%	4.4%	2.5%
Net Margin %	-4.0%	-14.1%	-114.5%	-47.9%	-5.5%	-21.2%	3.7%	-15.6%	7.2%	2.1%	2.5%	5.5%	-	3.9%	4.4%	2.1%	0.7%
ROE %	50.2%	109.3%	2,509.2%	191.7%	64.0%	736.1%	13.1%	2,534.7%	16.1%	6.0%	7.4%	11.4%	-	8.3%	9.9%	6.1%	2.9%
ROCE %	0.3%	273.3%	-136.9%	660.2%	-7.7%	-59.9%	3.9%	-172.7%	9.2%	20.1%	5.2%	11.5%	-	12.8%	11.8%	9.0%	4.9%

Shareholding Pattern

Insiders

22.85%

Institutions

66.17%

Public Float

85.77%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	19.27%	6.90M	$261.92M
2	Vanguard Portfolio Management LLC	7.28%	2.61M	$98.92M
3	Vanguard Capital Management LLC	5.44%	1.95M	$73.89M
4	State Street Corporation	4.86%	1.74M	$66.01M
5	325 Capital Llc	4.51%	1.61M	$61.26M
6	Dimensional Fund Advisors LP	4.10%	1.47M	$55.74M
7	Wellington Management Group, LLP	3.61%	1.29M	$49.07M
8	Geode Capital Management, LLC	3.26%	1.17M	$44.34M
9	Bank of America Corporation	2.38%	852.14K	$32.35M
10	FMR, LLC	1.92%	685.92K	$26.04M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ASTH

Google News hu, 03 Sep 2026

Here’s What Boosted Astrana Health (ASTH) in Q2 - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxObGRDaDE0MDVLUGVKMUFOcTkxUUpxQlJPSHhHdFdLYVhiTWM0bjhBLTlyUEx6YmU5UmNaWVFXVUJ3dzIxand0eXVEdnZMS2JzWnJGQ2VFeTg5TUZmb2lteGxMSnRxQndYSE5xS0ZPR1VqV2JEYUNDUkI2cjNEMTJjczJ3WUx3V0tTYmR3WW…

Google News Sat, 05 Sep 2026

Astrana Health (ASTH) In Focus After Diamond Hill Commentary As Valuation Narrative Builds - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxNaVRUS0NFQ3pNOUlHWjRlNVFXT29wQzVWTG1GTWxGOG4yS193V25LUmROY2ZKMlRTT1FzNFNQelgzZ1hUVHRqdE1WMW0zZU9TRG9LRUtvN1ZxaEpnSkJBMXVGTjVmZzVKV2NTTlJ2Rm8za0Y0Z0JKR0wyb0RqM051Zi1YelpiWnFmTzFmc2…

Google News Fri, 04 Sep 2026

How Apollo Medical Holdings Inc. (ASTH) Affects Rotational Strategy Timing - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPdm9kRHlJblBrTVVkRllGc2c2UkhVU1NiWFg3eHg0SVh2cGM5aC1JajFpTXZxVmtYbEpZOThBM0RHeE40MFVIakIweXNiaEZTenRzWmZJNmlLRWV4YlBGNVczd01aeXl5MVNQR2N1NTRId2MxbHRma2ZQMXAyMkRISFZUXzAzNW9Dd09ad2…

Google News ue, 18 Aug 2026

Astrana Health (NASDAQ: ASTH) director sells 20K shares back to company - Stock Titan

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOUTBRMG5RTUZXakFZajdSVm15WUxXTHlCb2J4Z0hDZGJiOWFRSzl5ME9lSlAtWE5vcy14YzltT3RIaFZwUE5JdzJwWDRweXk3WEFHdy1RM2dkUHNnNWFFTFNjWEQxc3h0MVhpaF9LcWQweVUxTDVISjJvZWZ2VEJxYjUzOTVPY01VTEs2Tj…

Google News hu, 06 Aug 2026

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non-GAAP EPS Estimates, Stock Soars 5.1% - StockStory

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQaHdYbGJuYXhlMjlGcVBxMTJURnBvUlNqWGt2X09TRXdacUdUcDN1TXZhLUNHYWxJU056Z0JqQ3BOZGc5U0J4ajU5cDhDQ1ZkYlFoY1pzS3lCQW5KXzNRMG9YaU0wWkpla2lJWUp3cloxZHJtUV9qdEV2dVJtSjVyUGpTdjNyaTlwSjEtUF…

Google News ue, 26 May 2026

ASTH - Astrana Health Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBVeEpIemxqbzk2cXo2OVA4N1NuMG1raHY4Unh5NGlJdl9GaXhVbjMwZXFORUdXWW9KNk5VV2N3QnRxT0tkUEE?oc=5" target="_blank">ASTH - Astrana Health Inc Stock Price and Quote</a>  <font col…

ASTH — Frequently Asked Questions

What is the current share price of Astrana Health, Inc. (ASTH)?

As of 2026-09-07 16:24 PDT, Astrana Health, Inc. (ASTH) trades at $38.47 on NasdaqCM. Its 52-week range is $18.16 to $49.81.

What is the market capitalisation of ASTH?

Astrana Health, Inc. (ASTH) has a market capitalisation of $1.91B on NasdaqCM.

What is the P/E ratio of ASTH?

ASTH trades at a trailing price-to-earnings (P/E) ratio of 63.07. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.19.

What is the return on equity (ROE) of ASTH?

ASTH has a return on equity (ROE) of 5.66%. Its return on capital employed (ROCE) is 4.90%.

Is ASTH a good stock to buy?

This page provides a data-driven analysis of Astrana Health, Inc. (ASTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Astrana Health, Inc. ASTH R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Here’s What Boosted Astrana Health (ASTH) in Q2 - Yahoo Finance

Astrana Health (ASTH) In Focus After Diamond Hill Commentary As Valuation Narrative Builds - simplywall.st

How Apollo Medical Holdings Inc. (ASTH) Affects Rotational Strategy Timing - Stock Traders Daily

Astrana Health (NASDAQ: ASTH) director sells 20K shares back to company - Stock Titan

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non-GAAP EPS Estimates, Stock Soars 5.1% - StockStory

ASTH - Astrana Health Inc Stock Price and Quote - Finviz

ASTH — Frequently Asked Questions

What is the current share price of Astrana Health, Inc. (ASTH)?

What is the market capitalisation of ASTH?

What is the P/E ratio of ASTH?

What is the return on equity (ROE) of ASTH?

Is ASTH a good stock to buy?

Explore More